Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Calcimedica Inc (CALC)

Calcimedica Inc (CALC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 7,439
  • Shares Outstanding, K 14,409
  • Annual Sales, $ 0 K
  • Annual Income, $ -13,700 K
  • EBIT $ -25 M
  • EBITDA $ -25 M
  • 60-Month Beta 0.49
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.49
  • Most Recent Earnings $-0.39 on 11/12/25
  • Next Earnings Date 03/26/26 [--]
  • Annual Dividend & Yield (Fwd) 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Options Overview Details

View History
  • Implied Volatility 441.55% (+103.41%)
  • Historical Volatility 413.45%
  • IV Percentile 65%
  • IV Rank 37.03%
  • IV High 1,150.52% on 01/16/26
  • IV Low 24.66% on 02/17/26
  • Expected Move (DTE 18) 0.2975 (58.68%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 1
  • Volume Avg (30-Day) 21
  • Put/Call OI Ratio 0.02
  • Today's Open Interest 551
  • Open Int (30-Day) 1,087
  • Expected Range 0.2095 to 0.8045

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.55
  • Number of Estimates 2
  • High Estimate -0.44
  • Low Estimate -0.66
  • Prior Year -0.34
  • Growth Rate Est. (year over year) -61.76%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.4606 +10.07%
on 03/02/26
0.7900 -35.82%
on 02/10/26
-0.1630 (-24.33%)
since 02/02/26
3-Month
0.4606 +10.07%
on 03/02/26
7.2000 -92.96%
on 01/02/26
-4.0930 (-88.98%)
since 12/02/25
52-Week
0.4606 +10.07%
on 03/02/26
7.2000 -92.96%
on 01/02/26
-1.7130 (-77.16%)
since 02/28/25

Most Recent Stories

More News
CalciMedica Announces Discontinuation of Phase 2 KOURAGE Trial in AKI Following Independent Data Monitoring Committee Recommendation

Safety concern warrants reevaluation of study design, including enrollment criteria

CALC : 0.5070 (-1.80%)
CalciMedica Reports Third Quarter 2025 Financial Results and Provides Clinical & Corporate Updates

Enrollment ongoing in Phase 2 KOURAGE trial of Auxora™ in acute kidney injury (AKI) with respiratory failure; data expected in 1H 2026

CALC : 0.5070 (-1.80%)
CalciMedica Announces Publication in JCI Insight of Preclinical Data Supporting CRAC Channel Inhibitor as a Potential Therapy for Pulmonary Arterial Hypertension

Preclinical data support CRAC channel inhibitor, CM5480, as a potential first-in-class, differentiated therapy for pulmonary arterial hypertension (PAH), both as monotherapy and in combination with existing...

CALC : 0.5070 (-1.80%)
CalciMedica Presents Data from Preclinical Study of Auxora™ in an Animal Model of AKI at ASN Kidney Week 2025

Treatment with Auxora significantly reduced IL-17–related inflammation in both kidney and lung, significantly increased glomerular filtration rate (GFR), and decreased renal injury in a rat model of...

CALC : 0.5070 (-1.80%)
CalciMedica and Telperian Announce Collaboration to Integrate Innovative Artificial Intelligence Engine to Analysis of Clinical Trials of Auxora™

AI tools will allow CalciMedica to analyze Phase 2 datasets to refine the target patient populations and efficacy endpoints for upcoming pivotal trials

CALC : 0.5070 (-1.80%)
CalciMedica to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

LA JOLLA, Calif. , Sept. 2, 2025 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica" or the "Company") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel...

CALC : 0.5070 (-1.80%)
Buy, Sell, or Hold? Insiders Pile Into These 3 Healthcare Stocks

Insiders are buying stocks like LLY, TFX, and CALC. The question is whether they are also a good buy for investors, and not all of them are.

TFX : 122.93 (+0.71%)
LLY : 1,017.97 (-3.23%)
CALC : 0.5070 (-1.80%)
CalciMedica Reports Second Quarter 2025 Financial Results and Provides Clinical & Corporate Updates

Enrollment ongoing in Phase 2 KOURAGE trial of Auxora™ in acute kidney injury (AKI) with respiratory failure; data expected in early 2026 

CALC : 0.5070 (-1.80%)
Insider Purchase: Director at $CALC (CALC) Buys 4,800 Shares

FRED A MIDDLETON, a director at $CALC ($CALC), bought 4,800 shares of the company on 12-06-2024. This trade was reported by Quiver Quantitative using data from a recent SEC filing. This increased their...

CALC : 0.5070 (-1.80%)
Insiders Bet Big on These Small Cap Stocks

Insiders are buying stocks like CalciMedica and BKV Corporation because they have value and catalysts in 2025 to drive higher share prices.

CALC : 0.5070 (-1.80%)
BKV : 31.27 (-0.19%)

Business Summary

CalciMedica Inc. is a clinical-stage biopharmaceutical company. It focused on developing therapies for life-threatening inflammatory diseases with high unmet need. CalciMedica Inc. is based in LA JOLLA, Calif.

See More

Key Turning Points

3rd Resistance Point 0.5924
2nd Resistance Point 0.5567
1st Resistance Point 0.5319
Last Price 0.5070
1st Support Level 0.4714
2nd Support Level 0.4357
3rd Support Level 0.4109

See More

52-Week High 7.2000
Fibonacci 61.8% 4.6255
Fibonacci 50% 3.8303
Fibonacci 38.2% 3.0351
Last Price 0.5070
52-Week Low 0.4606

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar